CCND2 is altered in 1.51% of malignant solid tumor patients with CCND2 Amplification present in 0.92% of all malignant solid tumor patients [4].

CCND2 Amplification is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 6 are open and 1 is closed. Of the trials that contain CCND2 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [5].

CCND2 is altered in 2.19% of malignant glioma patients with CCND2 Amplification present in 2.07% of all malignant glioma patients [4].

CCND2 Amplification is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain CCND2 Amplification and malignant glioma as inclusion criteria, 2 are early phase 1 (2 open) [5].

CCND2 is altered in 0.67% of non-hodgkin lymphoma patients with CCND2 Amplification present in 0.41% of all non-hodgkin lymphoma patients [4].

CCND2 Amplification is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND2 Amplification and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND2 is altered in 15.45% of germ cell tumor patients with CCND2 Amplification present in 15.73% of all germ cell tumor patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND2 Amplification and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND2 is altered in 2.47% of colorectal carcinoma patients with CCND2 Amplification present in 2.0% of all colorectal carcinoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND2 is altered in 2.55% of squamous cell lung carcinoma patients with CCND2 Amplification present in 1.11% of all squamous cell lung carcinoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CCND2 is altered in 1.52% of esophageal carcinoma patients with CCND2 Amplification present in 0.99% of all esophageal carcinoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND2 is altered in 1.42% of soft tissue sarcoma patients with CCND2 Amplification present in 0.75% of all soft tissue sarcoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND2 is altered in 1.11% of breast carcinoma patients with CCND2 Amplification present in 0.55% of all breast carcinoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 Amplification and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND2 is altered in 1.19% of osteosarcoma patients with CCND2 Amplification present in 0.44% of all osteosarcoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND2 is altered in 0.63% of gastric carcinoma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND2 is altered in 0.27% of meningioma patients [4].

CCND2 Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 Amplification and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].